Professor Stephen Mulligan

Adjunct Professor

G08 - Biochemistry and Microbiology Building
The University of Sydney


Research interests

Chronic Lymphocytic Leukaemia (CLL)

Keywords

Leukaemia; Proteomics; Haematology; Haematological malignancy; Immunology

Selected grants

2012

  • Next generation sequencing of TP53, ATM and a panel of novel target genes in an elderly clinical trial CLL cohort - correlation with cytogenetics, FISH and clinical outcomes; Badoux , Badoux X, Mulligan S, Ward C; CLL (Chronic Lymphocytic Leukemia) Global Research Foundation/Research Support.

2011

  • Patterns of differentially abundant proteins on progressive chronic lymphocytic leukaemias; Christopherson R, Mulligan S; Leukaemia Foundation of Australia/Grants in Aid.

2008

  • Proteomic responses of B-lymphoproliferative disorders to fludarabine; Christopherson R, Mulligan S; Leukaemia Foundation of Australia/Grants in Aid.

2006

  • Global phenotype profiling of chronic lymphocytic leukemia; Mulligan S, Christopherson R; CLL (Chronic Lymphocytic Leukemia) Global Research Foundation/Project Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Che, Y., Best, G., Zhong, L., Alexander-Kaufman, K., Mactier (nee Gez), S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Freeman, J., Crassini, K., Best, G., Forsyth, C., MacKinlay, N., Han, P., Stevenson, W., Mulligan, S. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 54(1), 99-104. [More Information]
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]
  • Best, O., Crassini, K., Freeman, J., Mulligan, S. (2013). The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal Of Infectious Diseases, 45(9), 729-729. [More Information]
  • Almazi, J., Mactier (nee Gez), S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Mulligan, S. (2012). Monoclonal B-lymphocytosis: reflections and definitions. Leukemia and Lymphoma, 53(9), 1647-1650. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia and Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia and Lymphoma, 53(7), 1367-1375. [More Information]
  • Henrich, S., Mactier (nee Gez), S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]
  • Cassano, C., Mactier (nee Gez), S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]
  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]
  • Henrich, S., Mactier (nee Gez), S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]
  • Mulligan, S. (2007). Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab - Double jeopardy. Leukemia and lymphoma, 48(10), 1885-1887. [More Information]
  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]
  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]
  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731.
  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]

2013

  • Che, Y., Best, G., Zhong, L., Alexander-Kaufman, K., Mactier (nee Gez), S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Freeman, J., Crassini, K., Best, G., Forsyth, C., MacKinlay, N., Han, P., Stevenson, W., Mulligan, S. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 54(1), 99-104. [More Information]
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]
  • Best, O., Crassini, K., Freeman, J., Mulligan, S. (2013). The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal Of Infectious Diseases, 45(9), 729-729. [More Information]

2012

  • Almazi, J., Mactier (nee Gez), S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Mulligan, S. (2012). Monoclonal B-lymphocytosis: reflections and definitions. Leukemia and Lymphoma, 53(9), 1647-1650. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia and Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia and Lymphoma, 53(7), 1367-1375. [More Information]

2011

  • Henrich, S., Mactier (nee Gez), S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]

2010

  • Cassano, C., Mactier (nee Gez), S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]

2009

  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]

2008

  • Henrich, S., Mactier (nee Gez), S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]

2007

  • Mulligan, S. (2007). Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab - Double jeopardy. Leukemia and lymphoma, 48(10), 1885-1887. [More Information]

2006

  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]

2005

  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]

2004

  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731.

2003

  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]

To update your profile click here. For support on your academic profile contact Research Support.